Cathepsin S inhibition would therefore be anticipated to have efficacy in CD4+ T cell–mediated autoimmune diseases and amelioration of disease in models of SLE, SS, inflammatory arthritis and multiple sclerosis has been observed [14, 17, 43, 44]. The gene discussed is CD4; the disease is systemic lupus erythematosus.